Background Limited data exists about night-time symptoms that are generated directly from patients with gastroesophageal reflux disease (GERD) who have a partial response to proton pump inhibitor (PPI) therapy. This information is needed to select an appropriate instrument in studies in this patient population. Objective The objective of this qualitative interview study was to gain understanding of the night-time symptoms of patients with GERD who had a partial response to PPIs. The specific aims were (i) to evaluate whether GERD symptoms experienced during the night differ from those occurring during the day; and (ii) to understand the impact of night-time symptoms on sleep and next-day functioning. Methods Four US sites participated in this study of patients with GERD who, despite PPI therapy for at least 4 weeks, still experienced both daytime and night-time heartburn and/ or regurgitation. Non-responders to PPIs were excluded. Patient statements were coded and grouped by concept.
Results Twenty-nine patients were enrolled. The predominant and most troublesome symptoms during both the day and night were heartburn and regurgitation. At nighttime only, expressions describing regurgitation were more frequent than those describing heartburn (62 vs. 26 %). During the daytime only, expressions describing regurgitation and heartburn occurred with similar frequency (21 vs. 27 %). Patients experienced greater severity of heartburn and regurgitation at night than during the day, and the difference was more pronounced for regurgitation. Patients focused on symptom frequency during the day but on symptom severity at night. Of expressions about the impact of night-time GERD symptoms, 46 % described impact on sleep and 41 % described compensatory behaviors when woken up by symptoms. Next-day impacts of night-time symptoms predominantly included changes in diet (53 %). Conclusions Partial responders to PPI therapy experience similar GERD symptoms at night and during the day. However, regurgitation is more predominant at night than during the day, and at night patients focus more on symptom severity than symptom frequency.
Key Points for Decision Makers
• In patients with gastroesophageal reflux disease (GERD) who have a partial response to proton pump inhibitor (PPI) treatment, regurgitation is more predominant at night than during the day, and at night patients tend to focus more on symptom severity than on symptom frequency.
• Impaired sleep and the impact of this on next-day functioning are extremely important consequences of night-time GERD symptoms.
Introduction
The estimated prevalence of gastroesophageal reflux disease (GERD) based on a definition of at least weekly heartburn and/or regurgitation symptoms in Western countries is 10-20 % [1] . Proton pump inhibitors (PPIs) are the most effective treatment for GERD and most patients achieve symptom resolution on PPIs [2, 3] . Nevertheless, evidence from interventional primary care trials suggests that the prevalence of persistent troublesome heartburn is 17 % and regurgitation is 28 % despite PPI therapy [4] .
Observations that GERD symptoms do not correlate well with the degree of esophageal injury [5, 6] has led to the concept of GERD as a symptom-driven disease. Symptoms are best captured using well-designed patientreported outcome (PRO) instruments, which can be a more comprehensive method of assessing symptoms than relying only on physician assessment. A prerequisite when developing PROs is to obtain evidence of the relevance of the PRO instrument to the specific target patient population [7] . Obtaining adequate patient input ensures the PRO instrument has content validity, and will capture all the symptoms experienced by the patient group and how the patients express their symptoms.
Symptoms of GERD can occur at any time of the day or night, and studies have shown that approximately threequarters of patients with GERD experience night-time symptoms [8, 9] . The nature and impact of night-time symptoms in patients with GERD have been characterized [10, 11] . While several questionnaires for GERD symptom assessment are available [12] [13] [14] , many have limitations in their ability to measure nocturnal symptoms [15] . In addition, validated questionnaires that inquire about the presence of nocturnal heartburn and regurgitation [16] , or at least mention that symptoms could occur during the night-time [17] , have tended to be initially developed based on expert input, rather than on input directly from the patient using the patients' own concepts and phrasing. Thus, there is a need for additional input from this patient population to give instruments content validity and ensure all relevant symptoms are captured. Furthermore, to our knowledge, information about night-time symptoms and their impact on patients with GERD who have not fully responded to PPI therapy is also lacking.
Conducting patient interviews is a key method for obtaining such detailed evidence, and the interview findings may motivate the development of a PRO capturing the specific nocturnal symptoms of this patient population.
Aims and Study Design
The objective of this study was to gain an understanding of night-time symptoms of patients with GERD who had a partial response to PPIs. The specific aims were (i) to evaluate whether GERD symptoms experienced during the night differ from those occurring during the day; and (ii) to understand the impact of night-time symptoms on sleep and next-day functioning.
This study was a multicenter, cross-sectional, qualitative interview study in patients with GERD, conducted in the US.
Methods

Sample Description
Patients were enrolled at four different sites in the US (large research centers in Minnesota, Arizona, and Washington State, and a private research practice in Idaho).
All patients had been diagnosed with GERD by a physician and had at least a 6-month history of GERD symptoms. All patients selected for enrollment were on optimized PPI regimen (i.e. a regimen that, according to the physician, could not be improved by changing the dose of the PPI) during the 4 weeks before interview. Patients with reflux esophagitis had been treated continuously with a PPI for at least 8 weeks before interview, with the last 4 weeks' treatment being with an optimized regimen. In addition, included patients had to have experienced a minimum of 3 days and 3 nights of at least mild severity of 'a burning feeling behind the breastbone' (heartburn) and/ or 'unpleasant movement of material upwards from the stomach' (regurgitation) during the week before interview. This inclusion criterion was based on a conservative definition of partial response that captures the proportion of patients with more frequent, residual symptoms, i.e. those with more problematic, residual symptoms [18] . To be included, patients also had to have a body mass index between 18.5 and 35.0 kg/m 2 . Non-responders to PPI treatment were excluded from this study. Furthermore, patients were excluded if a sleep disorder that was unrelated to GERD had been diagnosed, they had previously had surgery on the upper gastrointestinal tract, they were working night shifts, or they had a history of drug or alcohol abuse.
Measures
Data collection was conducted using (i) a screening questionnaire to identify patient eligibility according to inclusion/exclusion criteria; (ii) a clinician information document to describe relevant information about each patient's condition and treatment history; and (iii) a semistructured, qualitative interview guide containing both open-ended questions and structured probes.
Data Collection and Analysis
Following enrollment by clinical practitioners experienced in the diagnosis of GERD, patients were scheduled for individual, face-to-face, qualitative interviews. All interviews were held in March or April 2010. Appropriate Institutional Review Board (IRB) approval was obtained before study initiation. Patients completed a short descriptive demographics form and the Inclusion Symptom Questionnaire (ISQ), which asked about the frequency and severity of 'a burning feeling behind the breastbone' and 'unpleasant movement of material upwards from the stomach' during the day and night over the past week. Semi-structured, 1-hour interviews were performed by experienced interviewers trained in the best practice methods for conducting qualitative research related to clinical trial endpoints. The interview guides were designed to obtain both unprompted (spontaneous) and prompted (probed) patient expressions regarding the symptoms and impact of GERD, with a specific focus on sleep, emotions, and the ability to function. With consent from patients, each interview was audio-recorded and transcribed.
At the end of the open-ended qualitative portion of each interview, patients were given a rating worksheet and asked to rate (on a standard 11-point numerical rating scale [NRS]) the degree of bother they experienced due to each of the symptoms they had reported experiencing during the earlier part of the interview. The same process was used to rate how bothersome the impact of each symptom was on patients' lives. Patients were also asked about how they defined a successful GERD treatment.
Each concept identified in the interview transcripts was given a 'code' to allow the concept to be grouped with other codes of similar content. ATLAS.ti TM software (Cleverbridge, Chicago, IL, USA) was used to assist the coders in tagging the concepts, and cataloging the codes assigned. Three trained and experienced coders were used for this project. Two were also interviewers on this project and the remaining one was the team leader and supervisor for the coding function. Three randomly selected transcripts (10 % of the transcript database) were dual coded in order to assess inter-rater agreement (the consistency with which coders assigned codes to the concepts identified in the transcripts). In order to assess saturation (the point at which no more new information is being provided), the transcripts were grouped into quartiles, and codes reported for each subsequent quartile were compared with the codes for the preceding quartile until no new codes (thus no new information) appeared. The data collection and analysis techniques used in this study were based on current 'best practice' recommendations for establishing the content validity of PRO instruments for medical product evaluation [19] [20] [21] .
Results
Patient Demographics
A total of 29 patients were enrolled in the study across the four sites. Their mean age was 54 years (range 19-75 years) and 14 (48 %) were women. Eighteen patients (62 %) were White, eight (28 %) were Hispanic/Latino and three (10 %) were from other ethnic groups. On average, patients experienced their first GERD symptoms 7.7 years ago, and GERD was diagnosed 6.4 years ago. In line with inclusion criteria, all patients had at least mild heartburn and/or regurgitation at night and during the day in the week before interview (Table 1) , most of which was mild-to-moderate, although a considerable proportion had severe symptoms.
Saturation and Agreement
Saturation of the concepts was achieved by the end of the second quartile for both symptoms and impacts. Inter-rater agreement was high (77-87 % between coders for Table 1 Frequency and severity of daytime and night-time heartburn and regurgitation in the 7 days before the interview in the 29 patients included in the study assessed using the Inclusion Symptom Questionnaire successful identification of concepts, and 92-96 % between the coders for which code was assigned to an identified concept).
Symptoms Reported by Night and by Day
There were a total of 430 expressions in the transcript database describing symptoms experienced during both the day and night, 129 expressions describing daytime-only symptoms and 93 expressions describing night-time-only symptoms ( Table 2) . Irrespective of the time of day, the predominant symptom expressions were regurgitation and heartburn. Examples of patient quotes describing their symptoms are shown in the appendix (see electronic supplementary material). For night-time only, regurgitation was more predominant than heartburn in the reports of symptoms (62 % for regurgitation and 26 % for heartburn) and the most frequent expression for regurgitation was 'bitter taste' (20 %). For heartburn the most frequent expression was 'burning' (16 %). Difficulty swallowing, hoarseness, bloating, and burping were seldom experienced during the night.
For daytime-only symptoms, the frequencies at which regurgitation and heartburn were expressed were more similar (21 and 27 %, respectively) and heartburn expressions were grouped mostly into pain (12 %) and burning (9 %), whereas different regurgitation expressions were fairly evenly distributed.
When symptoms were experienced during the day and night, the proportion of expressions for heartburn and regurgitation were approximately equal (34 and 36 %, respectively).
Spontaneous and Probed Patient Responses
Patients reported their symptoms either spontaneously (in response to a general question), or in reply to a specific probe about any remaining symptoms over those already mentioned. Heartburn and regurgitation were reported primarily by spontaneous response (76 and 68 %, respectively). Burping was offered in similar proportions (52 % spontaneously), and hoarseness more often in response to probing (15 % spontaneously).
Impact of Night-Time GERD Symptoms
There were 432 patient expressions about the impact of night-time GERD symptoms (Table 3) . Of these, 46 % were about the impact on sleep and 41 % were about compensatory behaviors when woken up by their symptoms. The most frequently reported sleep impact was waking up (87 expressions) owing to GERD symptoms, which most commonly led to taking medicine (62 expressions).
There were 380 expressions about the next-day impact of night-time symptoms (Table 4) , primarily offered by spontaneous response. The most frequently mentioned next-day impact was a dietary change (200 expressions), most commonly involving the patient avoiding certain foods.
Differences Between Night-Time and Daytime Symptoms
Although the type of symptoms experienced during the night and during the day were similar, differences in symptom frequency and severity were observed. Patients more frequently reported regurgitation to occur at night relative to only during the day, and patients experienced a greater severity of heartburn and regurgitation at night than during the day. Also, patients' expressions illustrated a Burning 66 (15) 11 (9) 15 (16) Heartburn 37 (9) 4 (3) 2 (2) Pain 32 (7) 16 (12) (21) 58 (62) Acid taste 36 (8) 5 (4) 9 (10) Bitter taste 26 (6) 5 (4) 19 (20) Regurgitation into throat/ mouth 50 (12) 7 (5) 9 (10) Material coming upwards 21 (5) 4 (3) 9 (10) Vomiting 20 (5) 6 (5) 12 (13) Burping 55 (13) 17 (13) 4 (4) Difficulty swallowing
12 (3) 17 (13) a The overall symptom concept is shown in bold, and below each concept are the specific expressions used by patients as part of that concept trend towards focusing on symptom frequency during the daytime, and on symptom severity during the night. Furthermore, when patients were asked to define successful treatment, patients most often answered 'symptom resolution' (62 %), and this was more often for night-time symptoms than daytime symptoms.
Troublesome Ratings for GERD Symptoms and Impacts
The highest mean troublesome rating for symptoms was assigned to regurgitation (7.2), followed by heartburn (6.9), difficulty swallowing (6.8) and burping (6.0). The least troublesome symptoms were cough, bloating and hoarseness (5.6, 5.4, and 4.2, respectively). Regurgitation was the most troublesome symptom at night and, along with heartburn, was reported to be the most preferred symptom to treat. The highest mean troublesome rating that the patients assigned to the impact of symptoms was 8.4, given to the impact on sleep.
Discussion
This qualitative interview study evaluated daytime and night-time symptom patterns, and the impact of night-time symptoms on sleep and next-day functioning, in patients with GERD who had only a partial response to PPI therapy. The study was designed to elicit concepts using a thorough interview technique from the patient's perspective about what they feel to be relevant symptom experiences and the impact of their symptoms, both during the day and the night. Once per month 9 (2)
Once per week 23 (5) Once per night 3 (1)
Compensatory behaviors when woken up
(41)
Changing positions 54 (13) Drinking or eating 35 (8) Getting up from bed 24 (6) Taking medicine 62 (14) Bothersome aspects of night-time symptoms
(5)
More than one symptom experienced
How much symptoms interfered with sleep
(2)
How severe/intense symptoms were 12 (3)
GERD gastroesophageal reflux disease a The overall night-time impact concept is shown in bold, and below each concept are the specific expressions used as part of that concept Avoid drinking 21 (6) Avoid beverages that cause increased symptoms 25 (7) Drink beverages that calm symptoms 15 (4) Not eating 63 (17) Avoid food that causes increased symptoms 72 ( Impact on daily activity 26 (7) a The overall next-day impact concept is shown in bold, and below each concept are the specific expressions used as part of that concept
Results from this study indicate that the nature (but not the frequency or severity) of the symptoms experienced by partial responders at night is similar to that of symptoms experienced during the day. Furthermore, as has been found in the general GERD population [22, 23] , heartburn and regurgitation were reported as the most common symptoms during both the day and night. These data support earlier reports using instruments without fully documented content validity that patients with a partial response to PPI therapy experience the same symptoms as the general GERD population [24] [25] [26] .
However, patients who had both daytime and night-time heartburn and regurgitation indicated that they experienced greater severity of heartburn and regurgitation at night than during the day. A reason for this observation may be that during the night, when patients are in a horizontal position in bed, esophageal acid exposure may be of longer duration [27] . In addition, esophageal acid clearance is markedly prolonged during sleep [27] compared with during the daytime. This suggests that these patients may benefit from bedtime dosing of their PPI treatment [28] . Patients with night-time symptoms have also been shown in previous studies to find such symptoms more severe [8, 22] and more bothersome [29] than if they occurred mainly during the daytime. This may be best measured using instruments specifically designed to capture the severity of nocturnal symptoms [15] .
Although the Montreal definition of GERD [24] clearly states that both heartburn and regurgitation are the characteristic symptoms of the typical reflux syndrome, many studies exploring the relationship between GERD symptoms and sleep have focused on heartburn as the dominant symptom [8, 15, 30, 31] . However, this study demonstrates that regurgitation is an important symptom during the night in patients with a partial response to PPI treatment. Although patients indicated that they experienced greater severity of both heartburn and regurgitation at night than during the day, the difference was more pronounced for regurgitation, and patients more frequently reported regurgitation to occur only at night relative to only during the day. These findings are in agreement with reports that regurgitation is an important determinant of a partial response to PPI therapy in the general GERD population and is less responsive to PPI treatment than heartburn [32] .
The most common night-time-only regurgitation expression was 'bitter taste', whereas during the day the different regurgitation expressions were fairly evenly distributed. This may be explained by the physiological effect of acid mucosal contact during waking hours, when it normally results in increased saliva secretion, as well as an increase in the bicarbonate concentration of saliva. This clears the reflux and neutralizes the acid [27] . Therefore, patients may be more likely to notice a 'bitter taste' at night than during the day. A recent systematic review found that weakly acidic reflux underlies the majority of reflux episodes in patients with GERD on PPI therapy [33] .
Patients in this interview study tended to focus more on symptom frequency during the day, but on symptom severity at night. This may be because reflux events occur less frequently during stable sleep than during waking hours. However, the consequences of acid mucosal contact during sleep appear to be more detrimental since acid clearance is slower because primary peristalsis is largely absent during sleep [34] . In contrast to heartburn and regurgitation, other GERD symptoms were less frequently mentioned when patients were asked about night-time symptoms (e.g. hoarseness and difficulty swallowing were seldom experienced at night).
Patients considered heartburn and regurgitation to be the most troublesome symptoms and the symptoms that they would prioritize for treatment. Expressions regarding heartburn and regurgitation were offered primarily spontaneously and, to a lesser degree, by probing. In contrast, hoarseness was mentioned by patients more often in response to probing, possibly because patients did not associate hoarseness with GERD.
Patients commonly offered details of the next-day impact of their night-time symptoms by spontaneous response. The most frequently reported next-day impact was a dietary change, although patients also reported physical, emotional, and lifestyle impacts, as well as an impact on their partner, demonstrating the substantial effect night-time symptoms can have during the next day, in terms of body function, activities, and social participation.
Conclusions
The detailed data of this patient interview study indicates that patients with a partial response to PPI therapy experience similar GERD symptoms during the night as during the day. This suggests that a specific instrument to measure nocturnal symptoms in this patient population is not required. However, regurgitation is more predominant at night than during the day, and at night patients tend to focus more on symptom severity than on symptom frequency. Symptoms frequently affect sleep, which patients rate as highly troublesome, suggesting that impaired sleep and the impact of this on next-day functioning are extremely important consequences of GERD in patients with a partial response to PPI treatment.
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